Company Filing History:
Years Active: 1997-2006
Title: Discovering the Innovations of Udo Hahn
Introduction
Udo Hahn, a notable inventor based in Nentershausen, Germany, has made significant contributions to the field of pharmaceuticals. With a portfolio of five patents, his work focuses primarily on controlled release formulations that enhance the efficacy of analgesics. His dedication to innovation within the pharmaceutical industry showcases his expertise and commitment to improving patient care.
Latest Patents
Among Udo Hahn's latest inventions is the "Controlled Release Tramadol Formulation." This patent describes a controlled release preparation specifically designed for oral administration that contains tramadol or a pharmaceutically acceptable salt thereof as its active ingredient. Another notable patent is related to an "Opioid Analgesic," which addresses a pharmaceutical preparation designed for oral administration. This invention includes multiple active substances with formulation components that influence the release of these substances, achieving a specific in vitro release rate measured under the Ph. Eur. paddle test criteria. This innovation is crucial for providing targeted pain relief over extended periods.
Career Highlights
Udo Hahn currently works at Euro-Celtique S.A., where he has harnessed his expertise in developing pharmaceutical formulations. His innovative approaches have positioned him as a valuable asset in the industry, driving progress in pain management solutions and enhancing the efficacy of medications.
Collaborations
Throughout his career, Udo Hahn has collaborated with fellow professionals, including Walter Wimmer and Ronald Brown Miller. These partnerships have contributed to advancing research and development in the pharmaceutical field, fostering an environment of innovation that benefits both healthcare providers and patients.
Conclusion
Udo Hahn's inventive spirit and dedication to improving pharmaceutical formulations have resulted in impactful innovations within the industry. His work not only reflects his expertise but also exemplifies the ongoing need for advancements in medication that prioritize patient outcomes. As he continues to innovate, the potential for further contributions to pain management and beyond remains promising.